105 citations
,
August 2010 in “Pharmacology & therapeutics” Formyl-peptide receptor agonists could be new anti-inflammatory drugs.
August 2025 in “Bioactive Materials” Ac-GFFY-IGF peptide is a promising, safe, and effective treatment for hair loss, better than current options.
New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.
54 citations
,
December 2007 in “Best Practice & Research Clinical Endocrinology & Metabolism” Targeting glucocorticoid action might help treat type-2 diabetes, but human trials are needed.
March 2026 in “Journal of Pharmaceutical Research” Semaglutide is an effective weekly treatment for obesity, promoting weight loss and improving health, despite some side effects.
April 2023 in “Journal of The American Academy of Dermatology” Some drugs linked to growth hormones may increase the chance of hair loss in women.
5 citations
,
January 2015 in “Molecular Genetics and Metabolism” 8 citations
,
June 2004 in “Journal of Investigative Dermatology” Certain peptides can prevent hair loss in young rats caused by a cancer drug.
July 2026 in “Journal of Investigative Dermatology” GLP-1 therapies can cause hair loss, but hair often regrows after stopping or reducing the drug.
60 citations
,
May 2015 in “Archives of dermatological research” PPAR agonists show promise for skin conditions but need more research before being a main treatment.
58 citations
,
January 2015 in “Journal of the American Academy of Dermatology” Pioglitazone may help treat lichen planopilaris, but more research is needed.
12 citations
,
June 2019 in “Psychoneuroendocrinology” Allopregnanolone is needed for certain brain processing issues caused by D1 dopamine receptor activation.
CyRL-QN15 peptide boosts hair growth in diabetic mice by activating specific cell pathways.
13 citations
,
May 2011 in “Bioorganic & Medicinal Chemistry” Changing the 6-position on benzopyran molecules affects insulin release, with some compounds showing strong inhibitory effects.
38 citations
,
January 2017 in “PPAR Research” PPAR-γ helps control skin oil glands and inflammation, and its disruption can cause hair loss diseases.
43 citations
,
July 2013 in “Pharmacological reviews” New research on prostamide F2α has led to treatments for glaucoma and eyelash growth and may have more medical uses.
1 citations
,
June 2001 in “Annals of Internal Medicine” Troglitazone increases subcutaneous fat in lipodystrophy patients.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
April 2016 in “Journal of Investigative Dermatology” A peptide known for reducing wrinkles also effectively inhibits an enzyme linked to skin inflammation and acne.
11 citations
,
March 2024 in “Current Issues in Molecular Biology” Ginsenoside compound K shows promise for treating metabolic diseases like diabetes and obesity.
May 2026 in “Journal of Medicinal Chemistry” dAR-6–1 is a promising new treatment for hair loss that works better than minoxidil.
December 2023 in “PubMed” Metformin and liraglutide improved symptoms of HAIR-AN syndrome in a child.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
43 citations
,
August 2010 in “Expert Opinion on Investigational Drugs” Inhibitors of 11β-HSD1 show potential for treating type 2 diabetes but require more testing for safety and effectiveness.
15 citations
,
January 2024 in “Chemical Engineering Journal” May 2024 in “Archives of Dermatological Research” TAT-GILZ peptide promotes hair growth by boosting stem cell activity.
April 2019 in “Journal of the Endocrine Society” Androgens and estrogens are crucial for insulin secretion in males.
28 citations
,
November 2009 in “European Journal of Neuroscience” Progesterone and allopregnanolone increase glycine release in rat brain cells.
October 2024 in “Scientific Reports” OXTR agonists may promote hair growth and be effective for treating hair loss.
100 citations
,
May 2003 in “Journal of Neuroscience” Neuroactive steroids affect cocaine's rewarding effects through the ς1 receptor.